Literature DB >> 20739931

Slowing the decline.

Ruth Williams.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20739931     DOI： 10.1038/466S13a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  12 in total

1.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

Authors: 
Journal:  Arch Neurol       Date:  2004-04

Review 2.  A new look at levodopa based on the ELLDOPA study.

Authors:  S Fahn
Journal:  J Neural Transm Suppl       Date:  2006

3.  Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.

Authors:  M F Beal; R T Matthews; A Tieleman; C W Shults
Journal:  Brain Res       Date:  1998-02-02       Impact factor: 3.252

4.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Authors:  Clifford W Shults; David Oakes; Karl Kieburtz; M Flint Beal; Richard Haas; Sandy Plumb; Jorge L Juncos; John Nutt; Ira Shoulson; Julie Carter; Katie Kompoliti; Joel S Perlmutter; Stephen Reich; Matthew Stern; Ray L Watts; Roger Kurlan; Eric Molho; Madaline Harrison; Mark Lew
Journal:  Arch Neurol       Date:  2002-10

5.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Authors:  C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Authors:  William J Marks; Jill L Ostrem; Leonard Verhagen; Philip A Starr; Paul S Larson; Roy Ae Bakay; Robin Taylor; Deborah A Cahn-Weiner; A Jon Stoessl; C Warren Olanow; Raymond T Bartus
Journal:  Lancet Neurol       Date:  2008-04-02       Impact factor: 44.182

7.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

Authors: 
Journal:  Neurology       Date:  2006-02-15       Impact factor: 9.910

8.  Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

Authors:  C D Ward
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

9.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Authors:  J G Nutt; K J Burchiel; C L Comella; J Jankovic; A E Lang; E R Laws; A M Lozano; R D Penn; R K Simpson; M Stacy; G F Wooten
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

10.  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors:  Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422
View more
  1 in total

1.  Longitudinal deformation-based morphometry reveals spatio-temporal dynamics of brain volume changes in patients with corticobasal syndrome.

Authors:  Martin Südmeyer; Peter Pieperhoff; Stefano Ferrea; Holger Krause; Stefan Jun Groiss; Saskia Elben; Lars Wojtecki; Karl Zilles; Katrin Amunts; Alfons Schnitzler
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.